Enanta Pharmaceuticals Inc
ENTA7.100USD
-0.010-0.14%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
151.78MCap. mercado
PérdidaP/E TTM
Más Datos de Enanta Pharmaceuticals Inc Compañía
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Información de la empresa
Símbolo de cotizaciónENTA
Nombre de la empresaEnanta Pharmaceuticals Inc
Fecha de salida a bolsaMar 21, 2013
Director ejecutivoDr. Jay R. Luly, Ph.D.
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 21
Dirección4 Kingsbury Avenue
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Teléfono16176070800
Sitio Webhttps://www.enanta.com/
Símbolo de cotizaciónENTA
Fecha de salida a bolsaMar 21, 2013
Director ejecutivoDr. Jay R. Luly, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Desglose de ingresos
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
14.93M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
Accionistas
Accionistas
Proporción
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
35.82%
Hedge Fund
25.06%
Investment Advisor/Hedge Fund
23.43%
Individual Investor
6.69%
Research Firm
2.01%
Bank and Trust
0.30%
Family Office
0.20%
Sovereign Wealth Fund
0.19%
Pension Fund
0.15%
Other
6.14%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
315
20.05M
93.80%
-6.87M
2025Q1
342
20.11M
94.09%
-7.55M
2024Q4
348
21.38M
100.27%
-5.34M
2024Q3
354
22.65M
106.92%
-6.74M
2024Q2
352
23.60M
111.43%
-6.27M
2024Q1
361
24.29M
114.84%
-4.07M
2023Q4
373
21.96M
104.28%
-4.11M
2023Q3
375
22.04M
104.75%
-4.91M
2023Q2
376
21.98M
104.47%
-3.80M
2023Q1
380
21.64M
103.62%
-3.43M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Farallon Capital Management, L.L.C.
2.12M
9.93%
+14.00K
+0.66%
Mar 31, 2025
Krensavage Asset Management, LLC
2.12M
9.9%
-804.00
-0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.01M
9.39%
+23.27K
+1.17%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
8.05%
+3.27K
+0.19%
Mar 31, 2025
Millennium Management LLC
1.35M
6.3%
-35.34K
-2.56%
Mar 31, 2025
Acadian Asset Management LLC
867.04K
4.06%
+17.61K
+2.07%
Mar 31, 2025
Marshall Wace LLP
850.89K
3.98%
-79.20K
-8.52%
Mar 31, 2025
Luly (Jay R)
826.73K
3.87%
+62.57K
+8.19%
Feb 12, 2025
Stonepine Capital Management, LLC
590.74K
2.76%
+258.84K
+77.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
494.20K
2.31%
+16.97K
+3.56%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Avantis US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.57%
iShares Micro-Cap ETF
Proporción0.03%
Vanguard US Value Factor ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
